1 / 55

Bleeding and Anticoagulation

Bleeding and Anticoagulation. Dr Oliver Chapman 2011. Summary. Objectives: Understand haemostatic mechanisms Learn about the commoner haemorrhagic disorders and their treatment Understand how to initiate and manage anticoagulation Cases. Platelets. Platelet adhesion / aggregation.

caroline-lukas
Télécharger la présentation

Bleeding and Anticoagulation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bleeding and Anticoagulation Dr Oliver Chapman 2011

  2. Summary • Objectives: • Understand haemostatic mechanisms • Learn about the commoner haemorrhagic disorders and their treatment • Understand how to initiate and manage anticoagulation • Cases

  3. Platelets

  4. Platelet adhesion / aggregation

  5. Case Scenarios • Abnormal bleeding • “Peri operative screen” / Abnormal coagulation screen • Routine coagulation testing to predict postoperative bleeding risk in unselected patients prior to surgery or other invasive procedures is not recommended • A bleeding history, including family history, evidence of excessive post-traumatic or postsurgical bleeding and use of antithrombotic drugs should be taken in all patients prior to surgery or invasive procedures.

  6. Summary of key recommendations 1 Indiscriminate coagulation screening prior to surgery or other invasive procedures to predict postoperative bleeding in unselected patients is not recommended. (Grade B, Level III). 2 A bleeding history including detail of family history, previous excessive post-traumatic or postsurgical bleeding and use of anti-thrombotic drugs should be taken in all patients preoperatively and prior to invasive procedures. (Grade C, Level IV). 3 If the bleeding history is negative, no further coagulation testing is indicated. (Grade C, Level IV). 4 If the bleeding history is positive or there is a clear clinical indication (e.g. liver disease), a comprehensive assessment, guided by the clinical features is required. (Grade C, Level IV).

  7. Bleeding History • Include • Previous / current haemostatic challenges • Operation eg appendicectomy / T’s & A’s • Dental extractions • Lacerations / sutures • Menses • Drug History • Including anti platelet Rx / NSAID’s • Family history

  8. Laboratory tests Laboratory tests 1 • Platelets • FBC – platelet count and film • Bleeding time * • Platelet function tests (only at centres) * * =in liason with haematology

  9. Platelets - Blood film

  10. Bleeding Time

  11. Platelet function tests • If screening test abnormal and platelet count and VWD screen normal refer for platelet function test: • www.platelet-research.org

  12. Platelet disorders • Quantitative • Thrombocytopenia. • Qualitative • Functional disorders – Congenital vs Acquired

  13. Congenital platelet function disorders • Bernard Soulier • Rare. AR inheritance. Platelet GP Ib-IX deficiency – adhesion problem. • Glanzmann’s Thrombasthenia • Rare. AR inheritance. Platelet GP IIb-IIIa deficiency – aggregation problem. • Storage Pool Disorders • α-SPD (gray platelet syndrome) / Dense granule storage pool disorders (δ-SPDs) such as Chediak-Higashi, Hermansky-Pudlak syndrome, thrombocytopenia with absent radii (TAR syndrome), or Wiskott-Aldrich syndrome.

  14. Acquired platelet dysfunction disorders • Drugs eg aspirin, NSAID’s, clopidogrel, dipyridamole • Uraemia • Myelodysplastic , Myeloproliferative disorders

  15. Platelet disorders - treatment • Treatment of aquired platelet disorders • Stop offending drugs (aspirin – 7 days, other NSAID’s generally 1-2 days) • ddAVP in uraemia • Platelet transfusion (if active, significant bleeding aim to maintain platelets >50), otherwise >10. • NB Avoid platelet transfusions in HIT, TTP and PTP (unless life threatening bleeding)

  16. Laboratory tests • Laboratory tests 2 • Coagulation • Prothrombin Time (PT) • Activated Partial Thromboplastin Time (APTT) • Fibrinogen • Measurement of clotting factor levels * * =in liason with haematology

  17. Clotting factor disorders • Prothrombin Time • Normal 10-14s • Prolonged in deficiency Factor VII (and early warfarin) • APTT ratio • Normal • Prolonged in deficiency Factors VIII, IX, XI, XII • Both PT / APTT-R prolonged • Fibrinogen and other common pathway factors (FII, V, X) • NB International Normalised Ratio should only be used in the context of patients on warfarin

  18. Haemorrhagic disorders - coagulation • Prolonged coagulation screening test • Inhibitor (antibody - rare) vs Deficiency (common) • 50:50 mix • Deficiency : prolongation corrects • Inhibitor : no correction of prolongation

  19. Clotting factor deficiencies • Congenital • Acquired

  20. Congenital deficiencies • Haemophilia A, B • Joint, muscle bleeds • X linked • Other factors (very rare)

  21. Haemophilia • DO NOT DELAY TREATMENT • Delays in administration of clotting factor therapy / treatment significantly increase morbidity / costs of therapy and long term disability • Patients at UHCW when bleeding are ALL triaged orange minimum ie assessment in 30 minutes (and treatment within 60 minutes)

  22. Von Willebrands Disease • VWF carrier molecule for F VIII • VWF deficiency leads to VIII deficiency • Characterised by mucocutaneous bleeding (bruising, epistaxis, GI bleeds, menorrhagia) • Autosomal inheritance • Common (up to 1:1000)

  23. Acquired haemorrhagic coagulation disorders - • Acquired factor deficiencies • Warfarin • Vitamin K deficiency eg sick patients on broad spectrum antibiotics • DIC • Massive transfusion (whole blood volume replaced) • Liver disease

  24. Haemorrhagic disorders - treatment • Treatment of congenital factor deficiencies • Factor concentrates (except FV deficiency) NOT FFP or cryoprecipitate because of risks of viral transmission • Specialist involvement

  25. Haemorrhagic disorders - treatment • Treatment of acquired coagulation disorders if bleeding • PT / APTT prolonged – FFP 10-15mls /kg • Fibrinogen low – Cryoprecipitate (2 pools)

  26. Case 1 • 4 year old boy fell over and developed painful swelling of left elbow • What tests?

  27. Case 1 • FBC – normal • Coagulation screen • PT 12s (N) • APTR 2.0 (prolonged) • Fibrinogen 2.3 (N) • What are the possible diagnoses? • What tests? – bonus

  28. Case 2 • 76 yr old woman admitted with Right sided pneumonia, temp 39.5 C, bruising over arms, legs. • FBC – Hb 12.0, WCC 20.0, Platelets 22 • What test next?

  29. Case 2 • Coagulation screen • PT 20s • PTT 48s • Fibrinogen 0.7 • ? Likely diagnosis • What is the treatment? • If she were bleeding actively?

  30. Case 3 • 65 year woman with known atrial fibrillation admitted with haematemesis. • FBC – Hb 7.0, WCC 8, Platelets 190 • PT 40, APTT 34, Fibrinogen 2.0 • What is the likely cause? • How would you treat?

  31. Warfarin

  32. Warfarin in VTE - duration • Calf vein thrombosis - 3 months • Provoked proximal DVT eg post-op - 3 months • Idiopathic proximal DVT - 6 months • Pulmonary Embolism - 6 months • Recurrent DVT / PE - Indefinite • NB If persisting risk factor eg paralysis, immobilised limb / cancer consider extending treatment duration – INDIVIDUALISED THERAPY (the future?)

  33. Warfarin and AF • Risk factors for CVA in non-rheumatic AF include: • CCF, previous CVA, age > 75 yrs, hypertension, DM • Patients with no risk factors – stroke risk <1%/yr, treat with aspirin only – low CHAD2 score • Risk of serious bleeding on warfarin 2%, and of fatal bleeding 0.6% • Therefore consider whether warfarin indicated if lone warfarin. Also consider bleeding risk – increased if recurrent falls etc.

  34. Starting warfarin • 2 regimes based on degree of urgency for therapeutic anticoagulation • Rapid anticoagulation in patients requiring heparin ie post thrombosis etc • Slow induction of anticoagulation in outpatients not requiring heparin ie prophylaxis eg AF

  35. Rapid Warfarinisation • Gedge Nomogram - recommended • Shown to be safer than traditional Fennerty Nomogram in patients >65 years. • Similar time to achievement of therapeutic range (<1/7 difference) • Also concerns with Fennerty Nomogram in other patients with Congestive Cardiac Failure, Hepatic Dysfunction, other bleeding risks etc

  36. 1 Modified Fennerty Nomogram : Fennerty A et al (1984) Br Med J; 288: 1268-70 2 Gedge Nomogram : Gedge J et al (2000) Age and Ageing; 29: 31-34

  37. Non Urgent Warfarinisation • Liaise with anticoagulation team • Numerous equivalent low dose protocols eg Jane S et al (2004) Clinical Laboratory Pathology; 26: 43-47 • Still beware patients at risk of overanticoagulation eg amiodarone and consider reducing doses

  38. Warfarin Maintenance / Dose Modifications • Assuming target INR range 2-3 • INR<1.5 Increase by 1mg • INR 1.6-1.8 Increase by 0.5mg • INR 1.9-3.1 No change • INR 3.2-3.5 Reduce by 0.5 mg • INR 3.6-4.5 Omit dose, reduce by 0.5mg • INR 4.6-5.0 Omit dose, reduce by 1mg • INR 5.1-6.0 Omit 2 doses, reduce by 1mg • INR 6.1-8.0 Omit 3 doses and repeat • NB If interacting medication prescribed more frequent monitoring will be required

  39. Warfarin and Surgery • Individualized depending on risk of thrombosis (lone AF low risk vs. mechanical mitral valve high risk) vs. risk of bleeding. • In elective surgery • If low risk of thrombosis may be adequate to simply stop warfarin 4 days pre op and restart post op. Most operations can proceed safely with INR <1.5 (NB not neurosurgery) • If high risk may require bridging therapy with heparin when INR becomes sub therapeutic – discuss with senior colleague • Emergency surgery is likely to require reversal as per bleeding patients in all but minor procedures

  40. Warfarin overdose / bleeding • Overdose • INR >8.0 and no bleeding give oral Vitamin K (5mg) and inform anticoagulation team • Reversal agents / bleeding • Vitamin K • Oral – takes 24 hours to reduce INR – little use • IV – takes 6 hours to reduce INR • Fresh frozen plasma • 10-15 mls/kg ie large volume, usually takes 1-2 hours to administer • Prothrombin complex concentrate eg octaplex • Administer over 5-10 minutes slow IV push. Instantaneous reversal but risk of DIC / MI etc

  41. Heparin - uses • Prophylaxis vs. Therapeutic • Prophylaxis • No monitoring required (UFH or LMWH) • Generally give clexane 40 mg in most situations • Therapeutic • Monitoring mandatory daily + regular FBC with UFH/ intravenous heparin • Monitoring of LMWH generally not required

More Related